CDK4/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers
By
Junhao Cui
Yanchuan Zhang
Yongfang Wu
Guangjie Zhang
Jie Lan
Yingshuang Wang
June 4, 2026
Clinical Scorecard: Targeting CDK4/6 in Gastrointestinal Malignancies: Exploring Resistance Mechanisms and Biomarker-Driven Immunotherapy Combinations
At a Glance
Category Detail
Condition Key Mechanisms CDK4/6 inhibitors arrest the cell cycle at the G1/S checkpoint and remodel the tumor immune microenvironment, enhancing immune responses. Target Population Care Setting
Key Highlights
CDK4/6 inhibitors show potential in GI cancers despite slow development; however, resistance mechanisms differ from those in breast cancer. Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Monitor for primary and acquired resistance to CDK4/6 inhibitors, including specific biomarkers such as RB status and Cyclin D1 expression. Risks
Patient & Prescribing Data
Patients with advanced gastrointestinal malignancies.
Combination strategies are essential to overcome resistance and improve outcomes.
Clinical Best Practices
Utilize precision molecular subtyping for patient selection. Incorporate biomarker detection in treatment planning. Evaluate combination therapies to address resistance mechanisms, including monitoring for both primary and acquired resistance. Related Resources & Content
